

#9/K.T. 4/23 ISPH-0593 Revoc. 6/P.O.A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of) Group Art	Unit: 1635
Crooke and Graham) Examiner:	S. McGarry
Appln No. 09/919,197)	
Filed: July 31, 2001),	RECEIVED
For: ANTISENSE MODULATION OF SHORT HETERODIMER PARTNER-1 EXPRESSION)))	APR 1 6 2003
	77	OU OFFITTE

Commissioner for Patents Washington, D. C. 20231

TECH CENTER 1600/2900

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST AND REVOCATION OF PRIOR POWERS AND STATEMENT UNDER 37 CFR §3.73(b)

Sir:

As assignee of record of the entire interest of the above-identified application, ISIS PHARMACEUTICALS, INC. hereby revokes all powers of attorney previously given.

ISIS PHARMACEUTICALS, INC. hereby appoints the following attorney(s) and/or agent(s) to prosecute and transact all business in the United States Patent and Trademark Office connected with the above-identified application: Stanley B. Kita, Registration No. 24,561; George A. Smith, Jr., Registration No. 24,442; Mary E.

Certificate of Mailing under 37 CFR Section 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231 on Date

Typed or Printed Name of Person Signing Certificate

Bak, Registration No. 31,215; Cathy A. Kodroff, Registration No. 33,980; William Bak, Registration No. 37,277; Tracy U. Palovich, Registration No. 47,840; all of the firm of HOWSON AND HOWSON, of Spring House, Pennsylvania; and

Herb Boswell, Registration No. 27311; Laurel S. Bernstein, Registration No. 37,280; Neil S. Bartfield, Registration No. 39,901; Matthew Grumbling, Registration No. 44,427; Donna T. Ward, Registration No. 48,271, all of ISIS PHARMACEUTICALS, INC., of Carlsbad, California.

Address all telephone calls to Mary E. Bak at telephone No. (215) 540-9206. Address all correspondence to HOWSON AND HOWSON, Spring House Corporate Center, Box 457, Spring House, Pennsylvania 19477.

ISIS PHARMACEUTICALS, INC. certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors.

The evidentiary documents relating to the ownership of the above-identified application and the invention claimed therein have been reviewed, and consist of an assignment of the above-identified United States Patent Application No. 09/919,197 from the inventors to ISIS PHARMACEUTICALS, INC. The assignment was recorded at Reel 012467, Frame 0630 on January 10, 2001 at the United States Patent and Trademark Office.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above, and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned is empowered to sign this certificate on behalf of the assignee. To the best of the undersigned's knowledge and belief, title is solely in the assignee ISIS PHARMACEUTICALS, INC.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, or any patent issuing thereon.

ISIS PHARMACEUTICALS, INC.

DATE 4/4/03

RY

B Lynne Parshall

Executive Vice President

OIPE

PTO/SB/21 (03-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control
ar.

Application Number 09/919,197 Filing Date July 31, 2001 TRANSMITTAL First Named Inventor Crooke and Graham **FORM** Group Art Unit 1635 (to be used for all correspondence after initial filing) Examiner Name S. McGarry Attorney Docket Number ISPH-0593 Total Number of Pages in this Submission **ENCLOSURES** (check all that apply) Fee Transmittal Form Drawing(s) After Allowance Communication to Group Fee Attached Licensing-related Papers Appeal Communication to Board Amendment/Reply of Appeals and Interferences Petition Appeal Communication to Group After Final Petition to Convert to a (Appeal Notice, Brief, Reply Brief) **Provisional Application** Affidavits/declaration(s) Proprietary Information Power of Attorney, Revocation Change of Correspondence Address Extension of Time Request Status Letter Terminal Disclaimer Express Abandonment Request Other Enclosure(s) (please identify below): Request for Refund Information Disclosure Statement CD, Number of CD(s) **Certified Copy of Priority** Document(s) Remarks APR 1 6 2003 Response to Missing Parts/ Incomplete Application TECH CENTER 1600/2900 Response to Missing Parts under 37 CFR 1.52 or 1.53 -SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT **HOWSON AND HOWSON** Mary E. Bak, Esquire Individual Name Signature Date 4/09/03 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 4/9/03 postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Typed or printed name Diana M. Waligun Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option.